Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$163.95
+0.7%
$172.81
$130.96
$182.89
$290.30B0.615.60 million shs294,919 shs
GSK plc stock logo
GSK
GSK
$44.30
+2.0%
$41.90
$33.33
$44.33
$91.81B0.653.46 million shs421,924 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$765.25
-0.2%
$760.96
$419.80
$800.78
$727.30B0.373.06 million shs359,648 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.65%+0.75%-4.28%-6.08%+9.93%
GSK plc stock logo
GSK
GSK
-0.11%+4.37%+5.49%+4.08%+17.50%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+4.32%+3.99%-2.23%+8.76%+79.22%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.327 of 5 stars
1.43.04.23.92.62.51.9
GSK plc stock logo
GSK
GSK
3.0569 of 5 stars
0.03.03.30.03.20.02.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.5965 of 5 stars
2.43.02.54.02.61.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$174.316.32% Upside
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$757.95-0.95% Downside

Current Analyst Ratings

Latest GSK, LLY, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$900.00 ➝ $1,001.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$850.00 ➝ $900.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$850.00 ➝ $892.00
4/30/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00 ➝ $885.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$195.00 ➝ $187.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$195.00 ➝ $180.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.34$15.83 per share10.36$5.78 per share28.37
GSK plc stock logo
GSK
GSK
$37.71B2.43$5.28 per share8.39$7.74 per share5.72
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B21.31$7.94 per share96.37$11.44 per share66.89

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3748.6513.592.0711.02%165.18%14.40%7/25/2024 (Estimated)
GSK plc stock logo
GSK
GSK
$6.13B$2.7616.059.981.8514.62%51.54%11.01%7/24/2024 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$6.79112.7040.581.4517.08%56.98%10.94%8/13/2024 (Estimated)

Latest GSK, LLY, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024Q1 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.53$2.58+$0.05$2.68$8.94 billion$8.77 billion      
5/3/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.78%+7.84%183.98%52 Years
GSK plc stock logo
GSK
GSK
$1.593.59%-18.18%57.61%1 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.68%+15.15%76.58%10 Years

Latest GSK, LLY, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.37623.2%5/16/20245/17/20247/11/2024
5/6/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.300.69%5/16/20246/10/2024
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
GSK plc stock logo
GSK
GSK
1.15
0.87
0.58
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.90
1.35
1.03

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
GSK plc stock logo
GSK
GSK
15.74%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
GSK plc stock logo
GSK
GSK
10.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.41 million949.17 millionOptionable

GSK, LLY, and ABBV Headlines

SourceHeadline
Mutual Funds Cant Get Enough Amazon, BroadcomMutual Funds Can't Get Enough Amazon, Broadcom
finance.yahoo.com - May 7 at 9:52 AM
Eli Lilly and Company (NYSE:LLY) Trading 2.6% Higher  After Strong EarningsEli Lilly and Company (NYSE:LLY) Trading 2.6% Higher After Strong Earnings
americanbankingnews.com - May 7 at 1:34 AM
Welch & Forbes LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)Welch & Forbes LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - May 6 at 11:55 PM
Why Eli Lilly Stock Jumped by 4% TodayWhy Eli Lilly Stock Jumped by 4% Today
fool.com - May 6 at 7:06 PM
Eli Lilly and Company: Lilly Declares Second-Quarter 2024 DividendEli Lilly and Company: Lilly Declares Second-Quarter 2024 Dividend
finanznachrichten.de - May 6 at 6:51 PM
Eli Lilly First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagEli Lilly First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - May 6 at 6:51 PM
Eli Lilly and Company (NYSE:LLY) Declares Quarterly Dividend of $1.30Eli Lilly and Company (NYSE:LLY) Declares Quarterly Dividend of $1.30
marketbeat.com - May 6 at 2:15 PM
Eli Lilly and Company (NYSE:LLY) Trading Up 2.6% Following Earnings BeatEli Lilly and Company (NYSE:LLY) Trading Up 2.6% Following Earnings Beat
marketbeat.com - May 6 at 12:52 PM
Lilly Declares Second-Quarter 2024 DividendLilly Declares Second-Quarter 2024 Dividend
prnewswire.com - May 6 at 11:32 AM
Lilly (LLY) Reliance on International Sales: What Investors Need to KnowLilly (LLY) Reliance on International Sales: What Investors Need to Know
zacks.com - May 6 at 10:21 AM
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com - May 6 at 10:01 AM
Investors Pile Into Amgen in Search of Next Obesity Drug PayoutInvestors Pile Into Amgen in Search of Next Obesity Drug Payout
finance.yahoo.com - May 6 at 7:58 AM
Eli Lilly Gains on the GLP-1 Weight Loss PhenomenonEli Lilly Gains on the GLP-1 Weight Loss Phenomenon
marketbeat.com - May 6 at 6:15 AM
Eli Lilly Gains on the GLP-1 Weight Loss PhenomenonEli Lilly Gains on the GLP-1 Weight Loss Phenomenon
marketbeat.com - May 6 at 6:15 AM
2 Top Stocks That Could Make You Richer in 20242 Top Stocks That Could Make You Richer in 2024
fool.com - May 6 at 4:10 AM
Spire Wealth Management Boosts Holdings in Eli Lilly and Company (NYSE:LLY)Spire Wealth Management Boosts Holdings in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - May 6 at 12:57 AM
3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years
fool.com - May 5 at 2:49 PM
3 No-Brainer Stocks to Buy in May3 No-Brainer Stocks to Buy in May
fool.com - May 5 at 6:55 AM
JPMorgan Chase & Co. Raises Eli Lilly and Company (NYSE:LLY) Price Target to $900.00JPMorgan Chase & Co. Raises Eli Lilly and Company (NYSE:LLY) Price Target to $900.00
americanbankingnews.com - May 5 at 6:34 AM
Eli Lilly and Company (NYSE:LLY) Stock Price Down 3.2%Eli Lilly and Company (NYSE:LLY) Stock Price Down 3.2%
americanbankingnews.com - May 5 at 4:54 AM
Nations Financial Group Inc. IA ADV Boosts Stake in Eli Lilly and Company (NYSE:LLY)Nations Financial Group Inc. IA ADV Boosts Stake in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - May 5 at 12:48 AM
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
finance.yahoo.com - May 4 at 6:09 PM
Eli Lilly: Great Time To Divest Before It Potentially CrashesEli Lilly: Great Time To Divest Before It Potentially Crashes
seekingalpha.com - May 4 at 6:09 PM
Dont Wait for Fed to Cut Rates. Profit Now!Don't Wait for Fed to Cut Rates. Profit Now!
investorplace.com - May 4 at 12:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.